I believe that in addition to reducing the amount of patients required for the combo trial that the FDA also reduced the number of classes of drugs that the patient had to show resistance to. Originally, I think a patient had to show resistance to at least 1 drug in each class. I'd have to look back at previous conference calls to confirm this. If I have time, I'll take a look.